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Background: Since 1989 we have enrolled patients with clinical-
radiological stage III-IVA thymomas, independent of the surgeon’s
judgment of resectability, into a prospective study of neoadjuvant
chemotherapy–surgery and postoperative radiotherapy. In this arti-
cle, we review our long-term experience of neoadjuvant chemother-
apy of advanced stage (III-IVA) thymomas.
Methods: From 1989 to 2004, 30 patients with Masaoka stage III and
IVA thymomas underwent neoadjuvant chemotherapy, surgery, and
postoperative radiotherapy. The neoadjuvant and adjuvant chemother-
apy consisted of three courses of cisplatin, epidoxorubicin, and etopo-
side every 3 weeks. Adjuvant radiotherapy consisted of 45 Gy for
complete resections or 60 Gy for incomplete resections.
Results: The preoperative diagnosis of invasive thymomas was
obtained for 16 patients: five by mediastinotomy, seven by video-
assisted thoracic surgery, and four by fine needle aspiration. For 14
patients, no histological diagnosis was available, but a thymus-
related syndrome was present in all.
Twenty-seven patients are still alive (25 disease-free) and three have
died (one disease-free). The 10-year survival rates were 85.7% and
76.1% for stage III and IVA thymomas, respectively (difference not
significant). Only the World Health Organization pathological diag-
nosis significantly affected the survival, with type B3 having a worse
prognosis than type AB, B1, and B2 thymomas (p  0.02).
Conclusion: The multimodality treatment of stage III and IVA
thymomas by means of neoadjuvant chemotherapy provides good
long-term outcomes in both stages of the disease.
Key Words: Thymoma, Mediastinum, Multimodality treatments,
Neoadjuvant chemotherapy, Surgery.
(J Thorac Oncol. 2006;1: 308–313)
Thymomas are sensitive to chemotherapy, with responserates ranging from 70% to 100%.1–7 Chemotherapy in the
preoperative setting may, at least theoretically, convert inop-
erable disease to operable disease and reduce the incidence of
pleural and systemic relapses.2–3,8 In stage III and IVA thymo-
mas, complete surgical resection is not always achievable. Al-
though there are few randomized trials comparing surgery with
neoadjuvant chemotherapy, there is growing evidence that a
multimodality treatment including neoadjuvant chemotherapy is
effective in advanced-stage thymomas.4–7,9
We previously reported our preliminary experience on
neoadjuvant chemotherapy in thymic tumors,4 then consid-
ered exclusively the thymic carcinomas (type C), which
should be considered a distinct clinical entity.10 We now
report our experience with patients with stage III and IVA
thymomas who underwent multimodality treatments includ-
ing neoadjuvant chemotherapy.
In our preliminary study,4 the chemotherapy schedule
(cisplatin, epirubicin, and etoposide) resulted in a 100%
objective response rate with low toxicity; although it is not a
standard scheme, it includes three of the most effective drugs
in thymic cancers.
Recently, we decided to maintain the previous schedule
although new effective drugs are now available.8–9
PATIENTS AND METHODS
We prospectively investigated 30 patients with stage
III-IVA thymomas who underwent neoadjuvant chemother-
apy, surgery, and radiotherapy between 1989 and 2004 (Table
1). The diagnosis of thymoma was reviewed and confirmed
by our pathologist (F.B.) according to the World Health
Organization (WHO) classification;11 type C thymomas (thy-
mic carcinoma) were excluded from the present analysis.
Collection of data and follow-up were performed by
review of medical charts and phone contact or examination of
all patients. The eligibility criteria were: clinical radiological
stage III and IVA thymoma (histological diagnosis or pres-
ence of a clear thymus-related syndrome) patients younger
than 75 years no history of malignancy no prior chemother-
apy and/or radiotherapy Eastern Cooperative Oncology
Group (ECOG) performance status 0-3 adequate bone mar-
row reserve (leukocyte count 3500/l; platelet count
100,000/l) adequate liver (bilirubin1.5 mg/dl) and renal
(serum creatinine 1.5 mg/dl with creatinine clearance 65
ml/min) function.
All patients gave their written informed consent.
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There were 13 men and 17 women, with a mean age of
53.7 years (range, 25-74).
Preoperative staging included a complete history and
physical examination, serum titles of AchRAb and neurolog-
ical visit, chest radiography and computed tomography, chest
nuclear magnetic resonance in some cases, abdomen ultra-
sonography, and bone scan.
As previously described,4,10 the neoadjuvant chemo-
therapy consisted of three courses of intravenous cisplatin (75
mg/m2 on day 1), epirubicin (100 mg/m2 on day 1), and
etoposide (120 mg/m2 on days 1, 3, and 5) repeated every 3
weeks, depending on the patient’s hematological status and in
the absence of heart or general disorders.
Restaging was repeated 3 weeks after the third course;
patients then underwent surgery.
A complete exeresis of the tumor was always at-
tempted; whenever this proved impossible, the residual tumor
was clipped to better define the radiation therapy portals. A
resection that was microscopically incomplete was defined as
R1, whereas a grossly incomplete resection was defined as
R2. All patients underwent an extended thymectomy.12
Pre- and postoperative staging were performed accord-
ing to the staging system of Masaoka.13
Radiotherapy to the mediastinal or residual tumor areas
was performed using opposite anterior and posterior parallel
fields at doses of 45 Gy for complete resections or 60 Gy for
incomplete resections delivered over a period of 5 or 6 weeks,
respectively.
Whenever the resection was not complete or in the
presence of diffuse pleural spread, the patients were evalu-
ated for adjuvant chemoradiotherapy.
Survival was calculated from the date of the diagnosis
until the date of the last follow-up (April 1, 2005). The
statistical analysis was performed by using Stat-Soft soft-
ware. Results are expressed as mean  standard deviation.
Survival curves were estimated by the Kaplan-Meier’s prod-
uct-limit method14 and were compared by using the log-rank
test. The 2 test was used for comparison between propor-
tions, whereas Fisher’s exact test was used when the cell
frequencies were small. In this study, a p value less than 0.05
was considered significant in all comparisons.
RESULTS
Sixteen patients had no thymus-related syndrome, 12
myasthenia gravis (MG), 2 red cell aplasia (RCA).
The preoperative diagnosis of invasive thymomas was
performed for 16 patients: five by mediastinotomy, seven by
video-assisted thoracic surgery, and four by needle biopsy.
No diagnosis was available for 14 patients, but a thymus-
related syndrome suggested the diagnosis for all 14.
The total number of courses delivered was 89 (mean
interval between courses, 24.3 days). Median granulocyte,
platelet, and hemoglobin nadirs were 678/mmc, 127,000/
mmc and 10.9 g/dl, respectively; neutropenic fever occurred
in 23 courses (25.8%). The most common non-hematological
toxicities were alopecia and nausea/vomiting, usually mild or
moderate (Table 2). No epirubicin-related cardiotoxicity was
recorded during treatment. We observed severe hepatic tox-
icity in a young patient with a chronic hepatitis C, which
required stopping chemotherapy at the second course. For 22
patients, a major objective response was achieved, whereas
we did not experience any tumor progression.
The response was complete in two patients and partial
in 20. There was no correlation between objective response
rate and histologic type or stage of disease.
The surgical route was a median sternotomy for 26
patients and a sterno-thoracotomy for four. The resections
were complete in 23 cases and incomplete in seven cases (two
R1 and five R2). There was no postoperative mortality or
significant perioperative complication.
According to Masaoka staging, 20 patients had a stage
III thymoma and 10 a stage IVA. The postoperative patho-
logical diagnosis, reviewed according to the WHO histolog-
ical classification, showed three type AB thymomas, five B1,
seven B2, and 15 B3.
For adjuvant therapy, 21 patients underwent postoper-
ative radiotherapy, eight underwent chemo-radiotherapy, and
one underwent chemotherapy.
At a median follow-up of 94 months, 27 patients are
still alive (25 disease-free), whereas three have died (one
TABLE 1. Patient characteristics
Patients characteristics
Sex (M vs F) 13 vs 17
Age (years) 53.7 (range 25–74)
Staging of Masaoka
III
IVa
20
10
Thymus-related syndrome
Overall
Myasthenia gravis
Red cells aplasia
14
12
2
Histotype
AB
B1
B2
B3
3
5
7
15
Adjuvant therapies
CT
RT
CT-RT
1
21
8
CT, chemotherapy; RT, radiotherapy
TABLE 2. Non-hematological toxicity of neoadjuvant
chemotherapy by number of cycles
WHO Grade
Toxicity 0 1 2 3 4
Gastrointestinal 74 11 4 0 0
Alopecia 3 8 57 21 0
Infection 87 1 1 0 0
Cardiac 86 2 1 0 0
Nausea/vomiting 21 52 15 1 0
WHO, World Health Organization.
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disease-free). Nine patients have undergone further surgery:
seven for pleural implants, one for pleural and vertebral bone
metastasis, and one for mediastinal relapse. The two patients
who died of thymoma had multiple metastases (lung, liver,
and bone).
The overall 10-year survival rate was 82.4% (Fig. 1):
85.7%, and 76.2% for stage III and IVA thymomas, respec-
tively (Fig. 2).
Only the WHO pathological diagnosis significantly
affected the survival rate: patients with type B3 had a worse
prognosis than those with AB, B1, and B2 thymomas (p 
0.02) (Fig. 3). Although there was a favorable trend for
patients who underwent radical resection, the difference in
survival between the two groups was not statistically signif-
icant (Fig. 4).
CONCLUSION
Although most thymomas are early-stage and cured by
surgery, some patients with advanced disease, as well as other
thoracic malignancies, may benefit by a multimodality treat-
ment including neoadjuvant chemotherapy.3,8,15–16
Thymomas are sensitive to some cisplatin-based che-
motherapy regimens with PAC (cisplatin, doxorubicin, and
cyclophosphamide), ADOC (adriamycin, cisplatin, vincris-
tine, and cyclophosphamide), and CEVP-16 (cisplatin, epid-
oxorubicin, and etoposide); down-staging because of chemo-
therapy seems to improve the resectability rate with
acceptable morbidity and mortality.4–7
Given the rarity of thymomas, it is difficult to perform
a randomized trial comparing neoadjuvant chemotherapy
with primary surgery. We must therefore examine the single-
FIGURE 1. Overall survival of 30 patients with
stage III-IVA thymomas who underwent neoadju-
vant chemotherapy.
FIGURE 2. Survival according to the stage of
disease.
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institution experience, which prospectively evaluates the re-
sults of the neoadjuvant chemotherapy and compares them
with historical controls.5,17
In this study, we prospectively analyzed 30 patients
with stage III and IVA thymomas. Although this is a single-
institution experience, it is remarkable and with sufficient
follow-up to draw some considerations.
The selection of the patients was based on the pre-
operative work-up with computed tomography and/or
magnetic resonance. After 1989, all patients with clinically
radiologically advanced thymic tumors (stage III–IVA)
were enrolled into a prospective study of neoadjuvant
chemotherapy: surgery and postoperative radiotherapy.4
Although we paid attention to the selection of patients for
this protocol, we missed the clinical staging of a few
patients with thymomas who underwent primary surgery.
However, surgical exploration (by video-assisted thoracic
surgery, mediastinotomy, or thoracotomy) of all patients
with invasive thymomas is not advisable and may not
address important questions about the vascular invasive-
ness of the tumor.
Regarding thymus-related syndromes, we observed bet-
ter survival in patients with myasthenia gravis at the time of
diagnosis, but this difference was not statistically significant.
Indeed, we did not observe any deterioration of myas-
thenia gravis during chemotherapy or radiotherapy adminis-
tration. The improved medical therapy of myasthenia gravis
allows for safe control of the disease and should not be
considered a contraindication to any aggressive multimodal-
ity treatment.12
Looking at the WHO histological classification system,
we found that B3 thymomas (found in 50% of patients who
FIGURE 3. Survival according to the World Health
Organization histological classification of thymomas.
FIGURE 4. Survival according to the radicalism of
the operation.
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underwent neoadjuvant chemotherapy) had a more aggressive
clinical behavior with a significantly worse prognosis than the
other thymomas. This is in agreement with the findings of
other authors who analyzed their overall experience on the
surgical treatments of thymomas,18–21 but it is also significant
when considering only advanced stage disease. In two large
retrospective analyses, Strobel et al.22 and Park et al.23 found
an interesting correlation among tumor stage, WHO histo-
type, and radicalism of the resection; that is supported also by
our data.
Considering Masaoka staging, although patients with
stage III thymomas had a better survival rate, the difference
with patients with stage IVA thymomas was not statistically
significant. This may be the result of the small number of
patients in the analysis or of the heterogeneity of the sample.
It is a common opinion in most of the oncological
fields that radical resection is a main prognostic factor and,
at least theoretically, chemotherapy should reduce the
neoplastic mass, down-stage the disease, and increase the
resectability rate.
In our experience, thanks to a major response rate
greater than 75%, neoadjuvant chemotherapy increased the
complete resection rates both for stage III and for stage IVA
diseases, and patients undergoing a radical resection should
have a more favorable outcome.
However, comparing patients who had a radical resec-
tion with those who did not, despite a favorable trend, it was
not statistically significant.
This finding is in contrast with most reports on neoad-
juvant chemotherapy5,7 and should be considered in a multi-
center setting.
In any case, in a multimodality treatment that includes
postoperative radiotherapy, complete remission of disease
can be obtained with a surgical debulking as maximal as
possible. The role of radiotherapy for patients with stage III
disease is not yet clear; 24-26 however, in this set of patients,
we believe it is necessary to complete the clearance of the
tumor bed, also in case of a radical resection. The thymomas
included in our protocol were all greatly invasive at the
diagnosis, and we planned adjuvant radiotherapy in all cases.
As suggested by Detterbeck et al.27 in a recent review, the
reports questioning about the value of radiotherapy in stage
III thymomas are all retrospective and could have an impor-
tant bias in the selection of the patients. Therefore, according
to what we planned at the beginning of our experience, we
still offer adjuvant radiotherapy to all patients who undergo
neoadjuvant chemotherapy, independent of the radicalism of
the resection.
The role of adjuvant chemotherapy in the multimodal-
ity treatment of invasive thymomas is not clear; some do it,7
but we prefer to reserve it for patients without radical resec-
tion with tumor sites out of the radiotherapy field or for
eventual relapse not amenable of surgical resection. Most of
the chemotherapy regimens contain cisplatin, and good re-
sponse rates have also been reported in the metastatic setting.
In our preliminary experience,4 similar to what is re-
ported by other authors,7 we had two complete responses with
no tumor on the surgical specimens; unfortunately, we did not
experience any further complete response in the following
cases.
Induction chemotherapy proved to be effective in
down-staging thymomas and increasing the resectability rate,
but only a few reports5,17 had a sufficient follow-up to provide
the long-term outcome.
Within the limits of a non-randomized clinical trial, the
long follow-up of this analysis allows a main consideration:
neoadjuvant chemotherapy for patients with advanced-stage
thymomas results in survival rates that usually cannot be
obtained by primary surgery despite a negligible morbidity in
the perioperative course.
Although it still cannot be considered a standard treat-
ment for advanced-stage thymomas, there is now enough
evidence to suggest that thoracic surgeons who face this
disease should consider a multimodality treatment including
neoadjuvant chemotherapy as a valid option.
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